Orexo Q4 2025, Summary

Swedish pharmaceutical company Orexo AB has reported fourth quarter and full year 2025 results, highlighted by the completion of a major strategic transaction that has fundamentally reshaped the company's direction and financial foundation.

Major Divestment Strengthens Balance Sheet

On December 31, 2025, Orexo completed the sale of all US rights to Zubsolv®, its medication for opioid use disorder, to Dexcel Pharma USA. The transaction generated significant proceeds:

  • Upfront consideration of USD 91 million plus USD 3.8 million for inventory

  • Potential contingent payments of up to USD 16.8 million based on 2026-2027 net sales

  • Cash and cash equivalents increased to SEK 912.4 million from SEK 123.3 million in Q4 2024

  • Positive net cash position of SEK 429 million, compared to net debt of SEK 337 million a year earlier

The sale resulted in net income from discontinued operations of SEK 724.8 million for the quarter. Total comprehensive earnings for Q4 2025, including both continued and discontinued operations, were SEK 724.8 million, compared to a loss of SEK 116.2 million in the prior year period. Earnings per share for Q4 2025 was -3.33 SEK, reflecting the loss from continued operations offset partially by gains from discontinued operations.

Strategic Rationale and Future Focus

CEO Nikolaj Sørensen explained that the decision to divest Zubsolv, while significant, enables Orexo to secure most of the expected profitability from the product until patent expiry while becoming debt-free and refocusing resources. "The transaction enables Orexo to continue investments in the AmorphOX platform and our expanding pipeline of development programs," Sørensen stated.

The company is now positioning itself as a technology-driven pharmaceutical company built around its proprietary AmorphOX® powder-based drug delivery platform, which Sørensen described as "the most advanced nasal powder technology in the world.”

AmorphOX Technology Platform: The New Foundation

AmorphOX represents Orexo's core competitive advantage going forward. The technology provides unique properties that improve bioavailability and stability for both large and small molecules, enabling new approaches to drug administration, manufacturing, and distribution. Key advantages include:

  • Superior pharmacokinetic properties with rapid onset and higher exposure

  • Excellent chemical and physical stability at various temperatures

  • Versatility across small molecules, peptides, and biologics

  • Patent protection extending to 2044

The technology has been validated in multiple clinical trials, demonstrating rapid absorption, excellent bioavailability, and improved handling and storage properties.

Development Pipeline Progress

OX640 (Epinephrine for Anaphylaxis)

Orexo is on track to initiate the first pivotal trial for OX640, a powder-based intranasal epinephrine product for emergency treatment of allergic reactions including anaphylaxis, in Q4 2026. The product offers potential advantages over current treatments including superior absorption, longer shelf life, less restrictive storage requirements, and no need for preservatives. Patents protect the product until 2044.

OX390 (Adulterated Opioid Overdose Treatment)

This novel formulation, developed in partnership with the Biomedical Advanced Research and Development Authority (BARDA), addresses overdoses caused by opioids adulterated with animal tranquilizers like xylazine and medetomidine. BARDA is providing funding up to USD 51 million, covering the majority of development expenses. An in-vivo proof-of-concept study is planned for early 2026.

Izipry (High-Dose Naloxone)

The company is preparing to resubmit its registration application for Izipry, a high-dose naloxone rescue medication for opioid overdose, to the FDA in Q3 2026. Following the Zubsolv divestment, Orexo intends to partner for commercialization rather than pursuing direct sales.

OX472 (GLP-1 Agonist/Semaglutide)

Orexo is applying AmorphOX to develop an intranasal GLP-1 agonist, initially focused on semaglutide. Initial in-vivo studies showed promising pharmacokinetic data, and the company is working to optimize formulations to improve bioavailability further. The technology could enable needle-free administration with no refrigeration requirement and extended dosing intervals.

Vaccine Development

In collaboration with Abera Bioscience and leading vaccine experts, Orexo is developing an intranasal influenza vaccine combining AmorphOX with Abera's BERA™ vaccine platform. Proof-of-concept data demonstrated robust immune responses comparable to liquid nasal formulations, supporting the potential for thermostable, needle-free mucosal vaccines.

Three-Pillar Investment Strategy

Orexo outlined a clear strategy for deploying proceeds from the Zubsolv transaction across three areas:

  1. Continue developing the AmorphOX platform to enable new applications in peptides (such as GLP-1 agonists) and proteins (such as vaccines), generating proof-of-concept data through collaborations

  2. Advance proprietary projects to key value-inflection points such as pivotal clinical data or approval, then pursue commercialization primarily through partnerships

  3. Enter paid partnerships with pharmaceutical companies utilizing AmorphOX in their projects, with Orexo compensated through work performed plus future royalties and milestone payments

Financial Performance

Fourth Quarter 2025 Results

For Q4 2025, total net revenues were SEK 141.9 million, a decrease from SEK 160.3 million in Q4 2024. This included:

  • Zubsolv US product sales of SEK 138.6 million (USD 14.6 million), down from SEK 152.1 million in Q4 2024

  • Net revenues from continued operations of SEK 3.3 million

  • Operating loss from continued operations of SEK 103.2 million

  • EBITDA loss from continued operations of SEK 70.0 million

  • Total operating income (EBIT) for the company of SEK 753.0 million, driven by the gain on the Zubsolv divestment

Full Year 2025 Performance

For full year 2025, continued operations (excluding the divested Zubsolv US business) reported:

  • Net revenues of SEK 26.0 million (SEK 29.7 million in 2024)

  • Operating expenses of SEK 364.3 million (SEK 438.2 million), representing a decrease from the prior year

  • EBIT loss from continued operations of SEK 352.7 million (loss of SEK 427.2 million)

  • EBITDA loss from continued operations of SEK 285.7 million (loss of SEK 262.1 million)

  • Net loss from continued operations of SEK 403.3 million (loss of SEK 478.0 million)

  • Net cash flow from operating activities of SEK 811.0 million, driven primarily by proceeds from the Zubsolv divestment

Meeting 2025 Financial Targets

When excluding effects of the Zubsolv transaction, Orexo met its financial objectives for 2025, achieving positive EBITDA of SEK 3.2 million for the full year despite significant currency headwinds. Zubsolv US net sales for the full year reached USD 50.8 million (or USD 51.7 million excluding a non-recurring rebate payment), within the targeted range of USD 50-55 million.

Organizational Restructuring

The company is undertaking a restructuring to align its organization and cost base with the new strategic direction. During a transition period, portions of Orexo's operations will support Dexcel, with the restructuring expected to complete in autumn 2026. Most employees associated with Zubsolv US commercialization have transferred to Dexcel, while Orexo is reducing its US presence to a small office focused on development programs.

As of period end, Orexo employed 72 people, down from 110 a year earlier.

2026 Outlook and Priorities

Looking ahead to 2026, Orexo identified several key priorities:

  • Initiate the first pivotal trial for OX640

  • Analyze in-vivo data from OX390

  • Resubmit Izipry to the FDA

  • Progress development within peptides and vaccines

  • Expand paid partnerships utilizing the AmorphOX platform

The company plans to provide more detailed strategic plans at an R&D Day scheduled for March 24, 2026, at the Royal Swedish Academy of Engineering Sciences in Stockholm.

Market Context

Prior to divestment, Zubsolv maintained best-in-class market access in the US Commercial payer segment at 99 percent, with Public access at 48 percent. The broader buprenorphine/naloxone market grew 3 percent in 2024, with growth shifting from Medicaid (up 1 percent) to the Commercial segment (up 7 percent).

Financial Position and Capital Structure

The transformation leaves Orexo in a significantly stronger financial position:

  • Shareholders' equity of SEK 490.6 million (compared to negative SEK 126.3 million)

  • Total assets of SEK 1,302.8 million

  • Interest-bearing liabilities of SEK 483.1 million (a social bond maturing March 28, 2028)

  • Equity-to-assets ratio of 37.7 percent

The Board of Directors proposed no dividend for the 2025 financial year.

Conclusion

Orexo has executed a fundamental strategic transformation, converting a mature commercial asset into financial resources and organizational focus to build a technology-driven pharmaceutical company. With the AmorphOX platform validated across multiple applications, a diversified development pipeline addressing significant medical needs, and a strengthened balance sheet, the company is positioned to pursue growth through platform partnerships and proprietary product development. Success will depend on achieving clinical milestones, demonstrating the platform's versatility across therapeutic areas, and securing partnerships that validate both the technology and its commercial potential.

This summary was written by our AI Analyst Tim! If you find something that does not seem right let us know and we will correct him.